argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 41.74B +26.4% |
| Revenue (ttm) | 4.11B +79.4% |
| Net Income | 1.29B +39.9% |
| EPS | 19.51 +41.1% |
| Shares Out | 62.19M |
| PE Ratio | 34.41 |
| Forward PE | 26.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,098 |
| Average Volume | 85,610 |
| Open | 671.40 |
| Previous Close | 671.20 |
| Day's Range | 661.20 - 674.40 |
| 52-Week Range | 456.60 - 810.00 |
| Beta | -0.06 |
| RSI | 50.01 |
| Earnings Date | May 7, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Argenx (ARGX) to $1,170 from $1,230 and keeps an Overweight rating on the shares.
Argenx price target raised to $1,135 from $1,120 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Argenx (ARGX) to $1,135 from $1,120 and keeps a Buy rating on the shares. The firm adjusted estimates following the
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,260 from $1,247 and keeps an Overweight rating on the shares. The firm says Vyvgart’s growth remains durable with
Argenx price target lowered to $1,222 from $1,227 at Stifel
Stifel lowered the firm’s price target on Argenx (ARGX) to $1,222 from $1,227 and keeps a Buy rating on the shares following an in-line Q1 report. Despite seasonality headwinds, management
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of peo...
Pre-Market Earnings Report for May 7, 2026 : MCD, CNQ, HWM, SRE, LNG, TRGP, VST, GWW, ARGX, DDOG, ZTS, SHEL
The following companies are expected to report earnings prior to market open on 05/07/2026. Visit our Earnings Calendar for a full list of expected earnings releases.McDonald's Corporation (MCD)is rep...
argenx SE (XBRU:ARGX) Q1 2026: Everything You Need To Know Ahead Of Earnings
argenx SE (XBRU:ARGX) Q1 2026: Everything You Need To Know Ahead Of Earnings
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today an...
Noteworthy ETF Outflows: IBB, REGN, ARGX, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an appr...
argenx (ARGX) Reveals New Vyvgart Data at 2026 AAN Annual Meeting
argenx (ARGX) Reveals New Vyvgart Data at 2026 AAN Annual Meeting
Argenx announces Phase 3 Adapt Oculus study met primary endpoint
argenx (ARGX) announced the presentation of new data for Vyvgart in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy at the 2026 American Academy of Neurology, AAN, Annual Meeti...
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, O...
Wedbush Reaffirms ARGX, NUVB, FENC At Outperform; Lifts PT For Kiniksa; Keeps NVCR At Neutral
(RTTNews) - The biotech sector has always been a space where science, capital, and sentiment intersect in complex ways. From cautious optimism around breakthrough therapies to concerns over valuation ...
Oppenheimer Lowers Price Target for ARGX, Reiterates Outperform Rating | ARGX Stock News
Oppenheimer Lowers Price Target for ARGX, Reiterates Outperform Rating | ARGX Stock News
Argenx price target lowered to $1,014 from $1,060 at Oppenheimer
Oppenheimer analyst Leland Gershell lowered the firm’s price target on Argenx (ARGX) to $1,014 from $1,060 and keeps an Outperform rating on the shares. The firm made a variety of
Goldman Sachs Highlights Argenx (ARGX) as Prime Growth Opportunity
Goldman Sachs Highlights Argenx (ARGX) as Prime Growth Opportunity
Argenx added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added Argenx (ARGX) to the firm’s European Conviction List as part of its monthly update. Goldman views current share levels as a “compelling entry point into a
eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency
BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the...
Argenx upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis upgraded Argenx (ARGX) to Buy from Hold with a price target of EUR 725, up from EUR 675.
Deutsche Bank upgrades Argenx on Vyvgart momentum, less-demanding valuation
As previously reported, Deutsche Bank upgraded Argenx (ARGX) to Buy from Hold with a price target of EUR 725, up from EUR 675. Despite a “somewhat underwhelming” Q4 report on
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of pat...
argenx SE Transcript: TD Cowen 46th Annual Health Care Conference
The discussion outlined a robust growth and innovation strategy, with near-term clinical readouts in myositis, MMN, and Sjögren's, and a strong FcRn franchise expansion. VYVGART maintains leadership in MG, while new programs and flexible dosing aim to address unmet needs and broaden market reach.
These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
Argenx SE (NASDAQ: ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthen...
Argenx price target lowered to $890 from $925 at RBC Capital
RBC Capital lowered the firm’s price target on Argenx (ARGX) to $890 from $925 but keeps an Outperform rating on the shares after its Q4 results. The firm “remains buyers”